DRTS vs. PLSE, FNA, SIBN, OFIX, IRMD, BVS, SRDX, ANIK, OSUR, and NVRO
Should you be buying Alpha Tau Medical stock or one of its competitors? The main competitors of Alpha Tau Medical include Pulse Biosciences (PLSE), Paragon 28 (FNA), SI-BONE (SIBN), Orthofix Medical (OFIX), Iradimed (IRMD), Bioventus (BVS), Surmodics (SRDX), Anika Therapeutics (ANIK), OraSure Technologies (OSUR), and Nevro (NVRO). These companies are all part of the "surgical & medical instruments" industry.
Alpha Tau Medical (NASDAQ:DRTS) and Pulse Biosciences (NASDAQ:PLSE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.
Alpha Tau Medical has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Pulse Biosciences has a beta of 1.73, meaning that its stock price is 73% more volatile than the S&P 500.
Pulse Biosciences received 234 more outperform votes than Alpha Tau Medical when rated by MarketBeat users. Likewise, 65.17% of users gave Pulse Biosciences an outperform vote while only 61.90% of users gave Alpha Tau Medical an outperform vote.
Alpha Tau Medical's return on equity of -33.47% beat Pulse Biosciences' return on equity.
2.7% of Alpha Tau Medical shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 39.5% of Alpha Tau Medical shares are owned by company insiders. Comparatively, 71.5% of Pulse Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Alpha Tau Medical and Alpha Tau Medical both had 7 articles in the media. Alpha Tau Medical's average media sentiment score of 1.09 beat Pulse Biosciences' score of 0.74 indicating that Alpha Tau Medical is being referred to more favorably in the media.
Alpha Tau Medical has higher earnings, but lower revenue than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Alpha Tau Medical, indicating that it is currently the more affordable of the two stocks.
Alpha Tau Medical presently has a consensus price target of $12.00, indicating a potential upside of 389.80%. Given Alpha Tau Medical's higher probable upside, research analysts clearly believe Alpha Tau Medical is more favorable than Pulse Biosciences.
Summary
Alpha Tau Medical beats Pulse Biosciences on 8 of the 14 factors compared between the two stocks.
Get Alpha Tau Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRTS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alpha Tau Medical Competitors List
Related Companies and Tools
